Loading…
The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs
Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one S...
Saved in:
Published in: | Brain research 2010-11, Vol.1362, p.150-159 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3 |
---|---|
cites | cdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3 |
container_end_page | 159 |
container_issue | |
container_start_page | 150 |
container_title | Brain research |
container_volume | 1362 |
creator | Alonso-Alconada, Daniel Alvarez, Francisco J Alvarez, Antonia Mielgo, Victoria E Goñi-de-Cerio, Felipe Rey-Santano, Maria C Caballero, Amale Martinez-Orgado, Jose Hilario, Enrique |
description | Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage. |
doi_str_mv | 10.1016/j.brainres.2010.09.050 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_856757740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S000689931002055X</els_id><sourcerecordid>856757740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</originalsourceid><addsrcrecordid>eNqFks9u1DAQxiMEokvhFSpfEBeyTOw4di4IVPGnUgUHiuBmOfak65A_i50g9tZ34A15Ema1W5C49GTZ8_tmPvmbLDsrYF1AUb3o1k20YYyY1hzoEeo1SLiXrQqteF7xEu5nKwCocl3X4iR7lFJHVyFqeJidcNBSl1W9ym6uNsicHUfbhHEKnkV0uJ2nyOz1NIY0sy8XH5iUz3nBc05VvzhMbCZVGMMcbM8cRiQzPfN2sNfIbDtjZJvddvoZ3O-bXyG5DQ7BkaBb4o4O1uJMfG-HJj3OHrS2T_jkeJ5mn9--uTp_n19-fHdx_voyd6Uu55z7ygrXVlJAK3WjSq-gVFTzKEsvRONs3Th0QgqupdRKaF07zlXDa9W0Xpxmzw59t3H6vmCazUDGsO_tiNOSjJaVkkqVcCepKlGoklwRWR1IF6eUIrZmG8Ng484UYPYxmc7cxmT2MRmoDcVEwrPjiKUZ0P-V3eZCwNMjYJOzfRvt6EL6xwnyqQpF3KsDh_R1PwJGk1zA0aEPFORs_BTu9vLyvxaup2hp6jfcYeqmJY4UjClM4gbMp_1S7XeqAOAg5VfxB3l5ycU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>763174484</pqid></control><display><type>article</type><title>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</title><source>Elsevier</source><creator>Alonso-Alconada, Daniel ; Alvarez, Francisco J ; Alvarez, Antonia ; Mielgo, Victoria E ; Goñi-de-Cerio, Felipe ; Rey-Santano, Maria C ; Caballero, Amale ; Martinez-Orgado, Jose ; Hilario, Enrique</creator><creatorcontrib>Alonso-Alconada, Daniel ; Alvarez, Francisco J ; Alvarez, Antonia ; Mielgo, Victoria E ; Goñi-de-Cerio, Felipe ; Rey-Santano, Maria C ; Caballero, Amale ; Martinez-Orgado, Jose ; Hilario, Enrique</creatorcontrib><description>Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage.</description><identifier>ISSN: 0006-8993</identifier><identifier>EISSN: 1872-6240</identifier><identifier>DOI: 10.1016/j.brainres.2010.09.050</identifier><identifier>PMID: 20858469</identifier><identifier>CODEN: BRREAP</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Apoptosis ; Benzoxazines - pharmacology ; Benzoxazines - therapeutic use ; Biological and medical sciences ; Brain damage ; Calcium Channel Blockers - pharmacology ; Calcium Channel Blockers - therapeutic use ; Cannabinoid ; Cannabinoid Receptor Modulators - pharmacology ; Cannabinoid Receptor Modulators - therapeutic use ; Disease Models, Animal ; Female ; Fetus ; Hypoxia-Ischemia, Brain - drug therapy ; Hypoxia–ischemia ; Medical sciences ; Morpholines - pharmacology ; Morpholines - therapeutic use ; Naphthalenes - pharmacology ; Naphthalenes - therapeutic use ; Neurology ; Neuropharmacology ; Neuroprotective Agents - pharmacology ; Neuroprotective Agents - therapeutic use ; Pharmacology. Drug treatments ; Pregnancy ; Pregnancy Complications - drug therapy ; Psychodysleptics: hallucinogen ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Sheep, Domestic ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Brain research, 2010-11, Vol.1362, p.150-159</ispartof><rights>Elsevier B.V.</rights><rights>2010 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</citedby><cites>FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23403717$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20858469$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alonso-Alconada, Daniel</creatorcontrib><creatorcontrib>Alvarez, Francisco J</creatorcontrib><creatorcontrib>Alvarez, Antonia</creatorcontrib><creatorcontrib>Mielgo, Victoria E</creatorcontrib><creatorcontrib>Goñi-de-Cerio, Felipe</creatorcontrib><creatorcontrib>Rey-Santano, Maria C</creatorcontrib><creatorcontrib>Caballero, Amale</creatorcontrib><creatorcontrib>Martinez-Orgado, Jose</creatorcontrib><creatorcontrib>Hilario, Enrique</creatorcontrib><title>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</title><title>Brain research</title><addtitle>Brain Res</addtitle><description>Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Benzoxazines - pharmacology</subject><subject>Benzoxazines - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain damage</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cannabinoid</subject><subject>Cannabinoid Receptor Modulators - pharmacology</subject><subject>Cannabinoid Receptor Modulators - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Fetus</subject><subject>Hypoxia-Ischemia, Brain - drug therapy</subject><subject>Hypoxia–ischemia</subject><subject>Medical sciences</subject><subject>Morpholines - pharmacology</subject><subject>Morpholines - therapeutic use</subject><subject>Naphthalenes - pharmacology</subject><subject>Naphthalenes - therapeutic use</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Neuroprotective Agents - pharmacology</subject><subject>Neuroprotective Agents - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Psychodysleptics: hallucinogen</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Sheep, Domestic</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0006-8993</issn><issn>1872-6240</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNqFks9u1DAQxiMEokvhFSpfEBeyTOw4di4IVPGnUgUHiuBmOfak65A_i50g9tZ34A15Ema1W5C49GTZ8_tmPvmbLDsrYF1AUb3o1k20YYyY1hzoEeo1SLiXrQqteF7xEu5nKwCocl3X4iR7lFJHVyFqeJidcNBSl1W9ym6uNsicHUfbhHEKnkV0uJ2nyOz1NIY0sy8XH5iUz3nBc05VvzhMbCZVGMMcbM8cRiQzPfN2sNfIbDtjZJvddvoZ3O-bXyG5DQ7BkaBb4o4O1uJMfG-HJj3OHrS2T_jkeJ5mn9--uTp_n19-fHdx_voyd6Uu55z7ygrXVlJAK3WjSq-gVFTzKEsvRONs3Th0QgqupdRKaF07zlXDa9W0Xpxmzw59t3H6vmCazUDGsO_tiNOSjJaVkkqVcCepKlGoklwRWR1IF6eUIrZmG8Ng484UYPYxmc7cxmT2MRmoDcVEwrPjiKUZ0P-V3eZCwNMjYJOzfRvt6EL6xwnyqQpF3KsDh_R1PwJGk1zA0aEPFORs_BTu9vLyvxaup2hp6jfcYeqmJY4UjClM4gbMp_1S7XeqAOAg5VfxB3l5ycU</recordid><startdate>20101129</startdate><enddate>20101129</enddate><creator>Alonso-Alconada, Daniel</creator><creator>Alvarez, Francisco J</creator><creator>Alvarez, Antonia</creator><creator>Mielgo, Victoria E</creator><creator>Goñi-de-Cerio, Felipe</creator><creator>Rey-Santano, Maria C</creator><creator>Caballero, Amale</creator><creator>Martinez-Orgado, Jose</creator><creator>Hilario, Enrique</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>20101129</creationdate><title>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</title><author>Alonso-Alconada, Daniel ; Alvarez, Francisco J ; Alvarez, Antonia ; Mielgo, Victoria E ; Goñi-de-Cerio, Felipe ; Rey-Santano, Maria C ; Caballero, Amale ; Martinez-Orgado, Jose ; Hilario, Enrique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Benzoxazines - pharmacology</topic><topic>Benzoxazines - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain damage</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cannabinoid</topic><topic>Cannabinoid Receptor Modulators - pharmacology</topic><topic>Cannabinoid Receptor Modulators - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Fetus</topic><topic>Hypoxia-Ischemia, Brain - drug therapy</topic><topic>Hypoxia–ischemia</topic><topic>Medical sciences</topic><topic>Morpholines - pharmacology</topic><topic>Morpholines - therapeutic use</topic><topic>Naphthalenes - pharmacology</topic><topic>Naphthalenes - therapeutic use</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Neuroprotective Agents - pharmacology</topic><topic>Neuroprotective Agents - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Psychodysleptics: hallucinogen</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Sheep, Domestic</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alonso-Alconada, Daniel</creatorcontrib><creatorcontrib>Alvarez, Francisco J</creatorcontrib><creatorcontrib>Alvarez, Antonia</creatorcontrib><creatorcontrib>Mielgo, Victoria E</creatorcontrib><creatorcontrib>Goñi-de-Cerio, Felipe</creatorcontrib><creatorcontrib>Rey-Santano, Maria C</creatorcontrib><creatorcontrib>Caballero, Amale</creatorcontrib><creatorcontrib>Martinez-Orgado, Jose</creatorcontrib><creatorcontrib>Hilario, Enrique</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alonso-Alconada, Daniel</au><au>Alvarez, Francisco J</au><au>Alvarez, Antonia</au><au>Mielgo, Victoria E</au><au>Goñi-de-Cerio, Felipe</au><au>Rey-Santano, Maria C</au><au>Caballero, Amale</au><au>Martinez-Orgado, Jose</au><au>Hilario, Enrique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs</atitle><jtitle>Brain research</jtitle><addtitle>Brain Res</addtitle><date>2010-11-29</date><risdate>2010</risdate><volume>1362</volume><spage>150</spage><epage>159</epage><pages>150-159</pages><issn>0006-8993</issn><eissn>1872-6240</eissn><coden>BRREAP</coden><abstract>Abstract The aim of the present work was to evaluate in an early time point the effect of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic (HI) brain injury induced by partial occlusion of the umbilical cord of premature fetal lambs. Lambs were assigned to three experimental groups: one SHAM group: non-injured animals, and two hypoxic–ischemic groups that received a dose of 0.01 μg/kg WIN 55,212-2 (HI + WIN group) or not (HI +VEH) after 60 min of a hypoxic–ischemic event. All animals were managed on mechanical ventilation for 3 h and then sacrificed. Brains were perfusion-fixed and different regions separated for regional cerebral blood flow measurement, apoptosis quantification by TUNEL method and S-100 protein analysis by flow cytometry. The number of apoptotic cells was lower in the HI + WIN group in all regions studied. Moreover, animals treated with the cannabinoid agonist showed higher values in the percentage of S-100 positive cells in all regions, except in the cortex. In both studies we obtained similar values between SHAM group and HI + WIN group. Our results suggest that the administration of the cannabinoid agonist WIN 55,212-2 after hypoxic–ischemic brain injury in preterm lambs decreases brain injury reducing the delayed cell death and glial damage.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>20858469</pmid><doi>10.1016/j.brainres.2010.09.050</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-8993 |
ispartof | Brain research, 2010-11, Vol.1362, p.150-159 |
issn | 0006-8993 1872-6240 |
language | eng |
recordid | cdi_proquest_miscellaneous_856757740 |
source | Elsevier |
subjects | Animals Apoptosis Benzoxazines - pharmacology Benzoxazines - therapeutic use Biological and medical sciences Brain damage Calcium Channel Blockers - pharmacology Calcium Channel Blockers - therapeutic use Cannabinoid Cannabinoid Receptor Modulators - pharmacology Cannabinoid Receptor Modulators - therapeutic use Disease Models, Animal Female Fetus Hypoxia-Ischemia, Brain - drug therapy Hypoxia–ischemia Medical sciences Morpholines - pharmacology Morpholines - therapeutic use Naphthalenes - pharmacology Naphthalenes - therapeutic use Neurology Neuropharmacology Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Pharmacology. Drug treatments Pregnancy Pregnancy Complications - drug therapy Psychodysleptics: hallucinogen Psychology. Psychoanalysis. Psychiatry Psychopharmacology Sheep, Domestic Vascular diseases and vascular malformations of the nervous system |
title | The cannabinoid receptor agonist WIN 55,212-2 reduces the initial cerebral damage after hypoxic–ischemic injury in fetal lambs |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A03%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20cannabinoid%20receptor%20agonist%20WIN%2055,212-2%20reduces%20the%20initial%20cerebral%20damage%20after%20hypoxic%E2%80%93ischemic%20injury%20in%20fetal%20lambs&rft.jtitle=Brain%20research&rft.au=Alonso-Alconada,%20Daniel&rft.date=2010-11-29&rft.volume=1362&rft.spage=150&rft.epage=159&rft.pages=150-159&rft.issn=0006-8993&rft.eissn=1872-6240&rft.coden=BRREAP&rft_id=info:doi/10.1016/j.brainres.2010.09.050&rft_dat=%3Cproquest_cross%3E856757740%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c484t-2d6a3cf6530f58b74d7047c48de54d33bca9bcec3532855873889c227b297bfd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=763174484&rft_id=info:pmid/20858469&rfr_iscdi=true |